Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population

Cancer Causes and Control

Volumn 27, Issue 9, 2016, Pages 1127-1138

  Tao, Li ^a   Chu, Laura ^b   Wang, Lisa I ^b   Moy, Lisa ^a   Brammer, Melissa ^b   Song, Chunyan ^b   Green, Marjorie ^b   Kurian, Allison W ^c   Gomez, Scarlett L ^a,c   Clarke, Christina A ^a,c  

^a CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

De novo metastatic breast cancer; Subtype

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE; SOCIOECONOMICS; SURVIVAL RATE; SURVIVAL TIME; AFRICAN AMERICAN; BREAST NEOPLASMS; CALIFORNIA; INCIDENCE; METABOLISM; MIDDLE AGED; PROGNOSIS; SOCIAL CLASS;

AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; CALIFORNIA; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SOCIAL CLASS; SURVIVAL RATE;

EID: 84982267520     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-016-0791-9     Document Type: Article

References (52)

1. American Cancer Society (2013) Breast cancer facts and figures 2013–2014. American Cancer Society, Inc., Atlanta
2. Commission on Cancer—National Cancer Database (2007) Benchmark Reports, V 8.0-August 20, 2007—STAGE of Breast Cancer Diagnosed in 2004: Commission on Cancer—National Cancer Database (NCDB)
3. Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339:974–984
4. Bernard-Marty C, Cardoso F, Piccart MJ (2004) Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9:617–632
5. Lannin DR, Mathews HF, Mitchell J, Swanson MS, Swanson FH, Edwards MS (1998) Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA 279:1801–1807
6. Lee-Feldstein A, Feldstein PJ, Buchmueller T, Katterhagen G (2000) The relationship of HMOs, health insurance, and delivery systems to breast cancer outcomes. Med Care 38:705–718
7. Clegg LX, Reichman ME, Miller BA et al (2009) Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control 20:417–435
8. Breen N, Figueroa JB (1996) Stage of breast and cervical cancer diagnosis in disadvantaged neighborhoods: a prevention policy perspective. Am J Prev Med 12:319–326
9. Barry J, Breen N (2005) The importance of place of residence in predicting late-stage diagnosis of breast or cervical cancer. Health Place 11:15–29
10. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 38:698–707
11. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92–98
12. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502
13. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752
14. Sotiriou C, Wirapati P, Loi S et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272
15. Ramakrishna N, Temin S, Chandarlapaty S et al (2014) Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2100–2108
16. Giordano SH, Temin S, Kirshner JJ et al (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2078–2099
17. Lund MJ, Trivers KF, Porter PL et al (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357–370
18. O’Brien KM, Cole SR, Tse CK et al (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16:6100–6110
19. Yost K, Perkins C, Cohen R, Morris C, Wright W (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703–711
20. Yang J, Schupp CW, Harrati A, Clarke C, Keegan THM, Gomez SL (2014) Developing an area-based socioeconomic measure from American Community Survey data. Cancer Prevention Institute of California, Fremont
21. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728
22. Bernstein L, Lacey JV Jr (2011) Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative? J Natl Cancer Inst 103:451–453
23. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145
24. Surveillance, Epidemiology, and End Results (SEER) Program (2013) SEER*Stat database: incidence—SEER 18 Regs research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2013 Sub (1973–2011 varying)—Linked To County Attributes—Total U.S., 1969–2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014 (updated 5/7/2014), based on the November 2013 submission (www.seer.cancer.gov)
25. Leyland-Jones B (2009) Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27:5278–5286
26. Pestalozzi BC, Zahrieh D, Price KN et al (2006) Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935–944
27. Gabos Z, Sinha R, Hanson J et al (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658–5663
28. Welch HG, Gorski DH, Albertsen PC (2015) Trends in metastatic breast and prostate cancer-lessons in cancer dynamics. N Engl J Med 373:1685–1687
29. Khadakban D, Gorasia-Khadakban T, Vijaykumar DK, Pavithran K, Anupama R (2013) Factors associated with better survival after surgery in metastatic breast cancer patients. Indian J Surg Oncol 4:52–58
30. Bradley CJ, Given CW, Roberts C (2002) Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94:490–496
31. Zimmermann C, Swami N, Krzyzanowska M et al (2014) Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 383:1721–1730
32. Vaz-Luis I, Lin NU, Keating NL et al (2015) Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat 151:697–707
33. Tao L, Gomez SL, Keegan TH, Kurian AW, Clarke CA (2015) Breast cancer mortality in African-American and non-hispanic white women by molecular subtype and stage at diagnosis: a Population-Based Study. Cancer Epidemiol Biomark Prev 24:1039–1045
34. Baquet CR, Commiskey P (2000) Socioeconomic factors and breast carcinoma in multicultural women. Cancer 88:1256–1264
35. Schwartz KL, Crossley-May H, Vigneau FD, Brown K, Banerjee M (2003) Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control 14:761–766
36. Newman LA (2005) Breast cancer in African-American women. Oncologist 10:1–14
37. Mandelblatt JS, Yabroff KR, Kerner JF (1999) Equitable access to cancer services: a review of barriers to quality care. Cancer 86:2378–2390
38. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ (1999) Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 353:1119–1126
39. Aizer AA, Chen MH, McCarthy EP et al (2013) Marital status and survival in patients with cancer. J Clin Oncol 31:3869–3876
40. Cohen SD, Sharma T, Acquaviva K, Peterson RA, Patel SS, Kimmel PL (2007) Social support and chronic kidney disease: an update. Adv Chronic Kidney Dis 14:335–344
41. Goldzweig G, Andritsch E, Hubert A et al (2010) Psychological distress among male patients and male spouses: what do oncologists need to know? Ann Oncol 21:877–883
42. Carlson RW, Allred DC, Anderson BO et al (2012) Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10:821–829
43. Rapiti E, Verkooijen HM, Vlastos G et al (2006) Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 24:2743–2749
44. Ruiterkamp J, Voogd AC, Bosscha K, Tjan-Heijnen VC, Ernst MF (2010) Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Res Treat 120:9–16
45. Khan SA (2007) Does resection of an intact breast primary improve survival in metastatic breast cancer? Oncology (Williston Park). 21: 924-31; discussion 31-2, 34, 42, passim
46. Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA (2007) Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data. Ann Surg Oncol 14:2187–2194
47. Cady B, Nathan NR, Michaelson JS, Golshan M, Smith BL (2008) Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol 15:3384–3395
48. (2011) New therapies for metastatic disease addressed in updated NCCN Guidelines for breast cancer. J Natl Compr Canc Netw 9: xxxii–xxxiii
49. Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28:13–19
50. Baselga J, Cortes J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119
51. Verma S, Joy AA, Rayson D et al (2013) HER story: the next chapter in HER-2-directed therapy for advanced breast cancer. Oncologist 18:1153–1166
52. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743